Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escherichia coli Nissle 1917 + fructooligosaccharides + calcium carbonate
- Development stage
- Preclinical
- Lead developer
- Ardeypharm
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
REcN-F/Ca is a synthetically bioengineered probiotic consortium developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It consists of a reactive oxygen species (ROS)-tolerant strain of *Escherichia coli* Nissle 1917 (EcN), which has been iteratively selected for hydrogen peroxide resistance, and subsequently functionalized with a composite of fructooligosaccharides (FOS) and calcium carbonate (CaCO3). This formulation is designed to survive the harsh environment of the gastrointestinal tract and deliver therapeutic effects by reshaping the gut microbiota, specifically enriching butyrate-producing taxa such as Lachnospiraceae and Blautia. The resulting increase in short-chain fatty acids (SCFAs) and the activation of Peroxisome Proliferator-Activated Receptor (PPAR) signaling pathways lead to improved lipid metabolism, reduced adipose inflammation, and restored glucose homeostasis. In preclinical murine models, REcN-F/Ca has demonstrated significant efficacy in reducing weight gain, improving insulin sensitivity, and reversing metabolic dysfunction.
- Other names
- ROS-tolerant Escherichia coli Nissle 1917 + fructooligosaccharides + calcium carbonate
02
Targets
PPAR (PPAR family)
Beyond the preview
Go deeper on Escherichia coli Nissle 1917 + fructooligosaccharides + calcium carbonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Escherichia coli Nissle 1917 + fructooligosaccharides + calcium carbonate.